js_composer domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/wp-includes/functions.php on line 6121bridge domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/wp-includes/functions.php on line 6121
Delnova Announces First-In-Human Demonstration Of Reversal Of Neurotoxin Muscle Weakness
SAN DIEGO, Aug. 8, 2023 /PRNewswire/ DelNova Inc., is developing a rescue drug, ReViVox®, to resolve side effects that may result from botulinum neurotoxin treatment. Neurotoxins, such as Botox®, Dysport®, Xeomin®, Jeauveau® and, most recently, Daxxify®, are used for wrinkle reduction in facial aesthetics…
DelNova to be featured in the upcoming list of Top 10 Biotech Startups 2022
June 8, 2023 – DelNova to be featured in the upcoming list of Top 10 Biotech Startups 2022 as Editor’s Choice, on Life Sciences Review Magazine…
TREATING OF SIDE-EFFECTS RESULTING FROM CHEMODENERVATION
April 1, 2023: DelNova patent allowed in Europe
Women In Aesthetics Interview with Mary Gardner
June 1, 2022 – Mary Gardner has dedicated her entire career to the areas of innovation and commercialization for the pharma, biotech, and life science industries with positions across process design, technology, engineering, and project management…
Risk of Complications Associated With Botulinum Toxin (Bont) Injections, DelNova White Paper
May 3, 2022 – What are the complications associated with Botulinum Neurotoxin therapies? Neurotoxins are administered by medical professionals and sold in the US under the brand names Botox®, Dysport®, Xeomin® and most recently Jeaveau®. These are all important and relevant questions…
April 1, 2022 – DelNova announces advances in the development of the First ever product to reverse complications arising from botulinum toxins, such as BOTOX®, Dysport®, XEOMIN®…
March 15, 2022 Mary Gardner welcomes Dr. Steven Yoelin to the team as Chief Medical Advisor
Steve Yoelin, M.D. is a board-certified ophthalmologist based in Orange County, CA, with approximately 20 years of experience in minimally invasive medical aesthetics,…
September 28, 2021 DelNova had been granted US patent 11,129,822
DelNova’s patent portfolio covers key markets worldwide….
DelNova Selected to Present at Biotech Showcase – Seed Showcase, January 13, 2021
Watch the video presentation….
DelNova Selected to Present at the 2019 Start-Up Stadium during BIO 2019
May 29, 2019 – Presentation to highlight ReViVox™, DelNova’s lead product candidate designed for treating complications resulting from undesirable muscle paralysis following botulinum neurotoxin (e.g. Botox®) procedures…